STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
By
Andrew Joseph
2h ago
Source
STATSTAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and morestatnews.comNovartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
You might also wanna read
Cancer therapy spinout Myricx Bio agrees to US$1.5B acquisition by Novartis
Myricx Bio, a cancer therapy spinout from the Francis Crick Institute and Imperial College London, has agreed to be acquired by Novartis in
crick.ac.uk·2h agoBiotech NRx to sell new shares to fund growth and operations
stocktitan.net·1mo ago
A turning point for pancreatic cancer patients
statnews.com·1mo agoNovartis to buy UK biotech in $1.5bn deal
ft.com·7h ago
RQ Bio secures $115M Series A for virus-targeting antibody pipeline
endpoints.news·12d agoExperimental Novartis radiopharma drug shows promise in early study
reut.rs·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.